Barely Significant
← all excerpts

Rapidly evolving therapeutic advances for classical <i>EGFR</i>-mutant NSCLC.

Front Oncol · 2025 · PMC12719269 · PMID 41438982

Europe PMCDOI
1
hedged sentence
—
closest p
—
boldest claim

The sentences

showed a trendno p-value reported
Similar rates of treatment-related AEs and treatment discontinuation were observed with both treatments, and patritumab showed a trend towards improved CNS PFS (5.4 vs. 4.2 months; HR 0.75, 95% CI, 0.53-1.06.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.